Impact of PET on Intended Management for Restaging in Patients Older Than 65 Years
| Cancer | Time period | Patients (n) | Nontreatment to treatment (%) | Treatment to nontreatment (%) | Change in management (%) | 95% confidence interval | Imaging-adjusted impact (%)* | 95% confidence interval |
| Bladder | 2006 | 3,322 | 28.2 | 7.9 | 36.1 | 34.5–37.8 | 16.0 | 14.8–17.3 |
| 2009 | 5,539 | 29.4 | 5.9 | 35.3 | 34.0–36.6 | 12.8 | 11.9–13.7 | |
| Kidney | 2006 | 3,068 | 24.8 | 7.3 | 32.1 | 30.5–33.8 | 14.4 | 13.2–15.7 |
| 2009 | 4,708 | 27.2 | 5.8 | 33.0 | 31.6–34.4 | 12.7 | 11.7–13.6 | |
| Pancreas | 2006 | 2,876 | 31.6 | 8.6 | 40.2 | 38.4–42.0 | 16.5 | 15.1–17.9 |
| 2009 | 4,238 | 34.2 | 5.8 | 40.0 | 38.6–41.5 | 12.9 | 11.9–13.9 | |
| Prostate | 2006 | 4,856 | 27.7 | 10.2 | 37.8 | 36.5–39.2 | 16.0 | 15.0–17.0 |
| 2009 | 5,465 | 34.4 | 7.0 | 41.4 | 40.0–42.7 | 13.4 | 12.5–14.3 | |
| Small cell lung | 2006 | 2,810 | 33.0 | 7.8 | 40.7 | 38.9–42.6 | 15.2 | 13.9–16.5 |
| 2009 | 5,403 | 34.4 | 5.8 | 40.2 | 38.9–41.5 | 12.7 | 11.8–13.6 | |
| Stomach | 2006 | 2,281 | 23.1 | 8.1 | 31.2 | 29.3–33.1 | 12.9 | 11.5–14.3 |
| 2009 | 3,162 | 26.0 | 6.4 | 32.4 | 30.8–34.0 | 11.9 | 10.8–13.0 | |
| Uterus | 2006 | 3,367 | 26.4 | 7.5 | 33.8 | 32.2–35.5 | 14.8 | 13.6–16.0 |
| 2009 | 4,850 | 29.2 | 5.5 | 34.7 | 33.3–36.0 | 12.5 | 11.6–13.5 | |
| All other cancers | 2006 | 5,280 | 27.2 | 7.0 | 34.3 | 33.0–35.6 | 14.6 | 13.7–15.6 |
| 2009 | 15,466 | 27.6 | 5.8 | 33.4 | 32.7–34.2 | 12.4 | 11.9–12.9 | |
| Total | 2006 | 27,860 | 27.7 | 8.1 | 35.8 | 35.3–36.4 | 15.1 | 14.7–15.6 |
| 2009 | 48,831 | 29.9 | 6.0 | 35.9 | 35.4–36.3 | 12.6 | 12.3–12.9 |
↵* Imaging-adjusted impact: No benefit from PET was assumed for cases with a plan before PET of alternative imaging.